# Two-day CAR-T manufacture paired with rapid release tests that regulators accept

Source: https://onco.cc/ideas/idea-reg-two-day-cart-rapid-release/  
OnCo record `idea-reg-two-day-cart-rapid-release` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CAR-T can now be made in a day or two, but the safety tests to release it still take two weeks. Faster tests would let patients be treated within days.

## Summary

Non-expanded or minimally expanded CAR-T processes (Novartis T-Charge and rapcabtagene autoleucel, several academic protocols) produce a product in 24-48 hours, but release still waits for compendial 14-day sterility, mycoplasma and vector copy number assays. The proposal is a regulatory pathway for rapid release: validated rapid microbial methods (PCR- or growth-based, 24-72 hours), qPCR mycoplasma, flow-based potency surrogates, and 'release-then-confirm' with infusion permitted after rapid tests and compendial tests completed in parallel, as is already accepted for some cord blood and radiopharmaceutical products.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Rapid release cuts vein-to-vein time for fast-manufactured CAR-T to under seven days and reduces the proportion of enrolled patients who die or progress before infusion by half, with no increase in infusion-related infections.
- Rationale: Ten to twenty percent of patients referred for CAR-T never receive it, largely because of progression during the wait. Short manufacture also yields less differentiated, more persistent T cells. Rapid sterility methods are validated in blood banking and radiopharmacy where product shelf life forces the issue.
- Proposed test: Sponsor a regulator-endorsed validation study of rapid microbial methods against compendial methods on 500 CAR-T batches, then a prospective cohort using release-then-confirm with 30-day infection surveillance.
- Maturity: early-clinical
- Actor: regulator

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-two-day-cart-rapid-release.json